Melissa Lockett, NP
Acute Care · Glendale, AZNPI 1801366455
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AstraZeneca at 24.3% of the total. 2025 is the largest year on record at $2,980, more than ten times the $24 reported in 2021. Among acute care clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$810
- Sanofi$631
- GSK$341
- Insmed, Inc.$212
- Amgen$159
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,76295%
- Education$2425%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $1,214 |
| Regeneron Healthcare Solutions, Inc. | 31 | $810 |
| Sanofi | 25 | $631 |
| GSK | 26 | $341 |
| Insmed, Inc. | 15 | $212 |
| Amgen | 13 | $159 |
| Electromed, Inc. | 12 | $157 |
| Sanofi-aventis U.S. LLC | 2 | $152 |
| Mylan Specialty L.p. | 2 | $150 |
| Boehringer Ingelheim | 5 | $145 |
| United Therapeutics Corporation | 5 | $128 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $119 |
| Verona Pharma, Inc. | 4 | $116 |
| Actelion Pharmaceuticals US, Inc. | 3 | $90 |
| Inogen, Inc. | 6 | $87 |
| Viatris Specialty LLC | 3 | $77 |
| Genentech USA, Inc. | 2 | $68 |
| Inspire Medical Systems, Inc. | 3 | $65 |
| Phadia US Inc. | 2 | $40 |
| Harmony Biosciences LLC | 3 | $38 |
| Jazz Pharmaceuticals Inc. | 1 | $33 |
| Philips North America LLC | 1 | $28 |
| AbbVie | 1 | $24 |
| Grifols USA, LLC | 1 | $23 |
| Baxter Healthcare | 1 | $23 |
| Pfizer | 1 | $22 |
| Novartis | 1 | $20 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,004 in reported general payments places this provider in the 90th percentile of 482 acute care providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 559 | $450,299 |
| XolairOmalizumab | 20 | $86,199 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 126 | $76,964 |
| Spiriva RespimatTiotropium Bromide | 113 | $69,354 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 123 | $65,038 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 68 | $51,703 |
| EliquisApixaban | 46 | $35,127 |
| Incruse ElliptaUmeclidinium Bromide | 49 | $21,458 |
| Advair HfaFluticasone Propion/Salmeterol | 38 | $20,766 |
| SymbicortBudesonide/Formoterol Fumarate | 59 | $17,052 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 744 | $16,653 |
| Arnuity ElliptaFluticasone Furoate | 46 | $14,252 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 75 | $13,832 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $12,931 |
| Wixela InhubFluticasone Propion/Salmeterol | 54 | $6,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta, Breo Ellipta | $341 | $563,978800 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $145 | $146,318239 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,214 | $68,755127 claims |
| PfizerEliquis | $22 | $35,12746 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 482 acute care providers in Arizona.
Other acute care in Glendale
- Stephanie TironeGlendale$10K
- Nichole LeeGlendale$9K
- Jabez BarajasGlendale$9K
- Dana SochackiGlendale$8K
- Robin McLinnGlendale$5K
- Nicole CiffoneTucson$162K
- Kim KrmpoticPhoenix$79K
- Stephanie WilsonScottsdale$37K
- Laura Cook-GongoraPhoenix$32K
- Cathy PaynePhoenix$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.